Subcutaneous recombinant human erythropoietin and autologous blood donation before coronary artery bypass surgery.
Conventional therapies with recombinant human erythropoietin (rHuEPO) to sustain preoperative autologous blood collection entail high doses of the drug at short intervals. To evaluate the efficacy of a single weekly dose of rHuEPO for autologous blood collection, we randomly assigned 24 male patients scheduled for coronary artery bypass surgery to receive 400 IU/kg rHuEPO subcutaneously once a week or iron only. Patients were examined weekly and a total of up to 4 units of autologous blood were obtained if the hemoglobin level exceeded 12 g/dL. Patients receiving rHuEPO had consistently higher hemoglobin values than those receiving iron only (P < 0.001). Consequently, more autologous red cells were obtained from this group (776 +/- 49 mL vs 682 +/- 91 mL; P < 0.05). One patient receiving rHuEPO and eight in the control group required homologous blood at surgery (P < 0.01). These results suggest that 400 IU/kg rHuEPO administered subcutaneously once a week efficiently stimulates erythropoiesis and compensates the hemoglobin decrease after autologous blood donation.
Kulier
A H
AH
Department of Anesthesiology, University of Graz, Austria.
Gombotz
H
H
Fuchs
G
G
Vuckovic
U
U
Metzler
H
H
D001804:Blood Transfusion, Autologous; D001026:Coronary Artery Bypass; D004920:Erythropoiesis / Q000187:drug effects*; D004921:Erythropoietin / Q000494:pharmacology*; D006801:Humans; D007501:Iron / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011897:Random Allocation
D004921:Erythropoietin; D007501:Iron